USRE49518E1 - Fluorescent probe for detecting calpain activity - Google Patents

Fluorescent probe for detecting calpain activity Download PDF

Info

Publication number
USRE49518E1
USRE49518E1 US17/327,001 US201617327001A USRE49518E US RE49518 E1 USRE49518 E1 US RE49518E1 US 201617327001 A US201617327001 A US 201617327001A US RE49518 E USRE49518 E US RE49518E
Authority
US
United States
Prior art keywords
calpain
salt
hmrg
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US17/327,001
Inventor
Yasuteru Urano
Yuri Nagayo
Mako Kamiya
Toru Nakazawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
University of Tokyo NUC
Original Assignee
Tohoku University NUC
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC, University of Tokyo NUC filed Critical Tohoku University NUC
Priority to US17/327,001 priority Critical patent/USRE49518E1/en
Application granted granted Critical
Publication of USRE49518E1 publication Critical patent/USRE49518E1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Definitions

  • the present invention relates to a green fluorescent probe capable of detecting the activity of calpains.
  • the present invention also relates to diagnostic for retinal disease that uses the fluorescent probe.
  • Glaucoma is the number one cause of acquired blindness in adults in Japan, affecting an average of approximately 5% of those at least 40 years old.
  • the definition of glaucoma is “a disease characterized by functional, structural abnormality of the eye having characteristic changes in the optic nerve and visual field in which optic nerve damage can usually be improved or suppressed by lowering the intraocular pressure sufficiently” (Non-patent Reference 1).
  • Glaucoma is broadly classified as I) primary glaucoma, II) secondary glaucoma, and III) developmental glaucoma.
  • primary glaucoma is also classified as 1) glaucoma primary open-angle glaucoma (broad sense) (A: primary open-angle glaucoma, B: normo-tensive glaucoma), 2) primary closed-angle glaucoma (A: primary closed-angle glaucoma, B: iris plateau glaucoma), and 3) mixed glaucoma (Non-patent Reference 1).
  • Elevated intraocular pressure is one finding often seen in glaucoma, but in Japan normotensive glaucoma in which the intraocular pressure remains constantly at a normal value during the course of development and progress of the glaucoma accounts for approximately 70% of all glaucoma patients. This is a trend seen conspicuously in Asia.
  • the treatment method for glaucoma currently relied upon, however, is only lowering the intraocular pressure, and treatment methods for factors other than intraocular pressure are being sought.
  • Glaucoma in all its forms is characterized by the progressive disappearance of retinal ganglion cells (RGC) and corresponding visual field abnormalities.
  • RGC retinal ganglion cells
  • the disappearance of RGC has recently been suggested to be affected by calpain activity, and disappearance of RGC is reported to be decreased by administration of a calpain inhibitor in an animal model of normotensive glaucoma (Non-patent Reference 2).
  • RP retinitis pigmentosa
  • AMD age-related macular degeneration
  • Non-patent References 3-6 retinal neuropathy associated with diabetic retinopathy
  • retinal vascular occlusive diseases such as retinal vein occlusion and retinal artery occlusion, which are ischemic diseases (Non-patent References 7 and 8).
  • Calpains are cysteine proteases that act Ca 2+ -dependently. They are expressed universally in the central nervous system and are related to neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Calpains are expressed by RGC and the nerve fiber layer in the retina (Non-patent References 9-11), and activation of calpains is confirmed in the GCL (ganglion cell layer) of retinal grafts after axotomy and in rat glaucoma models (Non-patent References 12 and 13). Calpains indirectly induce an apoptosis pathway, and, as a result, are related to the disappearance of RGC.
  • GCL ganglion cell layer
  • the purpose of the present invention is to provide a fluorescent probe that detects calpain activity in cells at high sensitivity.
  • the purpose of the present invention is also to provide a diagnostic for retinal disease that, through the use of the fluorescent prove, permits real time monitoring of calpain activity and clarification of pathology, clinical diagnosis, and assessment of therapeutic effect in retinal neuropathy that progresses via activation of calpains in the field of ophthalmology.
  • a fluorescent probe the fluorescence of which rises during enzymatic reaction with calpains within cells can be provided by using HMRG as a basic skeleton and amide bonding a peptide chain to serve as a substrate for calpains, and completed the present invention.
  • the present invention provides:
  • R 1 is a hydrogen atom or from one to four of the same or different substituents that bond to the benzene ring;
  • R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are, each independently, a hydrogen atom, hydroxyl group, alkyl group, or halogen atom;
  • R 8 and R 9 are, each independently, a hydrogen atom or alkyl group
  • X is a C 1 -C 3 alkylene group
  • R 10 is a monovalent substituent cleaved by contact with calpain
  • a method for measuring calpain comprising the following steps: (a) a step for bringing a compound according to any of [1]-[5] or a salt thereof and calpain into contact and (b) a step for measuring the fluorescence intensity of the compound produced in step (a) after contact with calpain.
  • retinal disease is glaucoma, retinitis pigmentosa, age-related macular degeneration, or retinal neuropathy or retinal vascular occlusive disease associated with diabetes.
  • the use of the compound of the present invention makes it possible to provide a bright flourescent probe that can detect calpain activity in the green wavelength region, has excellent photostability, and a high quantum yield of the fluorescent substance generated by reaction with calpain.
  • the use of the compound of the present invention also makes it possible to provide a diagnostic of retinal diseases that permits real time monitoring of calpain activity in live cells, clarification of pathology, clinical diagnosis, and assessment of therapeutic effect in retinal diseases that progress via activation of calpain in the field of ophthalmology (for example, glaucoma, retinitis pigmentosa, age-related macular degeneration, retinal neuropathy or retinal vascular occlusive disease associated with diabetes, and other such retinal diseases).
  • ophthalmology for example, glaucoma, retinitis pigmentosa, age-related macular degeneration, retinal neuropathy or retinal vascular occlusive disease associated with diabetes, and other such retinal diseases.
  • the compound of the present invention can be observed by a fluorescein fluorescence fundus angiograph, which is already widely used in the field of ophthalmology, and is immediately applicable to actual clinical practice.
  • the present invention contributes to clarifying the pathology of retinal neuropathy that progresses via activation of calpain in the field of ophthalmology as a tool for monitoring calpain activity in live cells.
  • FIG. 1 a shows the changes in the absorption and fluorescence spectra of Ac-LLY-HMRG due to calpain addition (using calpain 1)
  • FIG. 1 b shows the changes in the absorption and fluorescence spectra of Ac-LLY-HMRG due to calpain addition (using calpain 2)
  • FIG. 2 a shows the changes in the absorption and fluorescence spectra of Ac-LM-HMRG due to calpain addition (using calpain 1)
  • FIG. 2 b shows the changes in the absorption and fluorescence spectra of Ac-LM-HMRG due to calpain addition (using calpain 2)
  • FIG. 3 shows live cell imaging using Ac-LLY-HMRG
  • FIG. 4 a shows live cell imaging using Ac-LM-HMRG (no ALLN added)
  • FIG. 4 b shows live cell imaging using Ac-LM-HMRG (1 ⁇ M of ALLN added)
  • FIG. 4 c shows live cell imaging using Ac-LM-HMRG (2 ⁇ M of ALLN added)
  • FIG. 4 d shows live cell imaging using Ac-LM-HMRG (5 ⁇ M of ALLN added)
  • FIG. 5 a is a fundus photograph of before Ac-LM-HMRG administration in the NMDA group
  • FIG. 5 b is a fundus photograph of 30 minutes after Ac-LM-HMRG administration in the NMDA group
  • FIG. 5 c is a fundus photograph of 60 minutes after Ac-LM-HMRG administration in the NMDA group
  • FIG. 5 d is a fundus photograph of 90 minutes after Ac-LM-HMRG administration in the NMDA group
  • FIG. 6 a is a fundus photograph of before Ac-LM-HMRG administration in the PBS group
  • FIG. 6 b is a fundus photograph of 30 minutes after Ac-LM-HMRG administration in the PBS group
  • FIG. 6 c is a fundus photograph of 60 minutes after Ac-LM-HMRG administration in the PBS group
  • FIG. 6 d is a fundus photograph of 90 minutes after Ac-LM-HMRG administration in the PBS group
  • FIG. 7 a is an FG stained image of a flat-mounted retina in the NMDA group
  • FIG. 7 b is an HMRG stained image of a flat-mounted retina in the NMDA group
  • FIG. 7 c is a Sytox (registered trademark) Orange stained image of a flat-mounted retina in the NMDA group
  • FIG. 8 a is an FG stained image of a flat-mounted retina in the PBS group
  • FIG. 8 b is an HMRG stained image of a flat-mounted retina in the PBS group
  • FIG. 8 c is a Sytox (registered trademark) Orange stained image of a flat-mounted retina in the PBS group
  • an alkyl group may be any alkyl group comprising linear, branched, cyclic, or a combination thereof.
  • the number of carbon atoms in the alkyl group is not particularly restricted; for example, about 1-6 carbon atoms or about 1-4 carbon atoms.
  • alkyl groups may have one or more optional substituents. Examples of substituents include, but are not limited to, an alkoxy group, halogen atom (may be any of a fluorine atom, chlorine atom, bromine atom, or iodine atom), amino group, mono- or di-substituted amino group, substituted silyl group, acyl group, or the like.
  • alkyl group When an alkyl group has two or more substituents, they may be the same or different. The same is also true for alkyl moieties of other substituents that include an alkyl moiety (for example, an alkyloxy group, aralkyl group, or the like).
  • an aryl group may be either a monocyclic aryl group or a fused polycyclic aryl group, and may include one or more heteroatoms (for example, an oxygen atom, nitrogen atom, sulfur atom, or the like) as ring members.
  • an aryl group may have one or more optional substituents on its ring. Examples of substituents include, but are not limited to, an alkoxy group, halogen atom, amino group, mono- or di-substituted amino group, substituted silyl group, acyl group, or the like. When an aryl group has two or more substituents, they may be the same or different. The same is also true for aryl moieties of other substituents that include an aryl moiety (for example, an aryloxy group, aralkyl group, or the like).
  • One embodiment of the present invention is a compound of the following general formula (I):
  • R 1 is a hydrogen atom or from one to four of the same or different substituents that bond to the benzene ring;
  • R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are, each independently, a hydrogen atom, hydroxyl group, alkyl group, or halogen atom;
  • R 8 and R 9 are, each independently, a hydrogen atom or alkyl group
  • X is a C 1 -C 3 alkylene group
  • R 10 represents a monovalent substituent cleaved by contact with calpain
  • R 1 represents a hydrogen atom or from one to four substituents that bond to the benzene ring.
  • substituents include, but are not limited to, an alkyl group, alkoxy group, halogen atom, amino group, mono- or disubstituted amino group, substituted silyl group, acyl group, or the like. When there are two or more substituents on the benzene ring, they may be the same or different.
  • a hydrogen atom is preferred as R 1 .
  • R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 each independently represent a hydrogen atom, hydroxyl group, alkyl group, or halogen atom.
  • R 2 and R 7 are preferably hydrogen atoms.
  • R 3 , R 4 , R 5 , and R 6 are also preferably hydrogen atoms. It is more preferred that R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are all hydrogen atoms.
  • R 8 and R 9 each independently represent a hydrogen atom or alkyl group.
  • R 8 and R 9 both represent alkyl groups, they may be the same or different.
  • R 8 and R 9 are both hydrogen atoms or when R 8 is an alkyl group and R 9 is a hydrogen atom. It is more preferred that R 8 and R 9 are both hydrogen atoms.
  • X represents a C 1 -C 3 alkylene group.
  • An alkylene group may be a linear alkylene group or a branched alkylene group.
  • a methylene group —CH 2 —
  • ethylene group —CH 2 —CH 2 —
  • propylene group —CH 2 —CH 2 —CH 2 —
  • —CH(CH 3 )— —CH 2 —CH(CH 3 )—
  • CH 3 —CH(CH 2 CH 3 )—
  • R 10 represents a monovalent substituent that is cleaved by contact with calpain.
  • a monovalent substituent including an oligopeptide residue is preferred as the monovalent substituent that is cleaved by contact with calpain.
  • Monovalent substituents including an oligopeptide residue having a sequence of Leu-Leu-Tyr, Leu-Met, Leu-Leu-Val-Tyr, Thr-Pro-Leu-Leu, Thr-Pro-Leu-Lys, Thr-Pro-Leu-Phe, and Leu-Try are preferred as monovalent substituents including an oligopeptide residue.
  • the N end of the monovalent substituent including an oligopeptide residue may be protected.
  • protecting groups include an acetyl group, glutaryl group, succinyl group, tert-butoxycarbonyl group, benzyloxycarbonyl group, and the like, but substituents other than these may be used.
  • the monovalent substituent including an oligopeptide residue is represented by the following formula (1) or (2).
  • One preferred embodiment of the present invention is a compound represented by the following formula (3) or (4), or a salt thereof.
  • salts of compounds represented by general formula (I) and formulas (3) and (4) in the present invention include base addition salts, acid addition salts, amino acid salts, and the like.
  • base addition salts include metal salts such as a sodium salt, potassium salt, calcium salt, magnesium salt, or the like, an ammonium salt, or an organic amine salt such as a triethylamine salt, piperidine salt, morpholine salt, or the like.
  • acid addition salts include mineral acid salts such as a hydrochloride, sulfate, nitrate, and the like, and organic acid salts such as a methanesulfonate, p-toluenesulfonate, citrate, oxalate, and the like.
  • organic acid salts such as a methanesulfonate, p-toluenesulfonate, citrate, oxalate, and the like.
  • amino acid salts include a glycine salt and the like. However, salts of compounds of the present invention are not limited to these.
  • Compounds represented by general formula (I) sometimes have one or more asymmetrical carbons in accordance with the types of substituents and can exist as stereoisomers such as optical isomers and diastereomers. Stereoisomers of a pure form, any mixtures of stereoisomers, racemic mixtures, and the like are all encompassed within the scope of the present invention.
  • compounds represented by general formula (I) or salts thereof can also exist as hydrates or solvates. All of these are encompassed within the scope of the present invention.
  • the type of solvent that forms a solvate is not particularly restricted; examples include ethanol, acetone, isopropanol, and other such solvents.
  • a fluorescent probe including a compound represented by general formula (I), formula (3), or formula (4) or a salt thereof provided by the present invention can generate a compound in which the absorption wavelength is shifted to a longer wavelength (corresponding to a compound in which R 10 in the above general formula (I) is a hydrogen atom) by cleaving the R 10 substituent or the monovalent substituent including an oligopeptide residue by contact with calpain, and can be used suitably as a fluorescent probe for measuring calpain.
  • Calpain can be measured using the above fluorescent probe in accordance with methods known to those skilled in the art.
  • the fluorescent probe can therefore also be used as a reagent for research and also as a reagent for diagnosis of humans and animals.
  • using the above fluorescent probe makes it possible to measure the concentration and amount of a substance to be measured in a test tube.
  • measurement is possible by causing the fluorescent probe to be taken up within living cells or a living body and imaging by a bioimaging technique.
  • a typical example is a method that includes the following steps: (a) a step for bringing a compound represented by general formula (I) having a monovalent substituent that is cleaved by contact with calpain or a salt thereof and calpain into contact and (b) a step for measuring the fluorescence intensity of the compound produced in step (a) after contact with calpain.
  • the method for using the fluorescent probe of the present invention is not particularly restricted. Examples include measurement of the activity of isolated, purified enzymes and calpain included in cell lysate, measurement of calpain activity in living cells, measurement of the activity of enzymes that serve as a cancer biomarker in living tissues making use of the long wavelength optical property, and the like.
  • Another embodiment of the present invention is a diagnostic for retinal diseases including a compound and salt of the present invention.
  • Another embodiment of the present invention is a diagnostic for retinal neuropathy that progresses via activation of calpain in the field of ophthalmology including a compound and salt of the present invention.
  • Yet another embodiment of the present invention is a diagnostic for glaucoma, retinitis pigmentosa, age-related macular degeneration, retinal neuropathy or retinal vascular occlusive disease associated with diabetes (retinal vein occlusion or retinal artery occlusion) including a compound and salt of the present invention.
  • Yet another embodiment of the present invention is a diagnostic for glaucoma including a compound and salt of the present invention.
  • Yet another aspect of the present invention is a diagnostic for normotensive glaucoma including a compound and salt of the present invention.
  • Compounds and salts of the present invention can detect calpain activity in the green wavelength region and have excellent photostability. Their use in the field of ophthalmology therefore permits clarification of the pathology, clinical diagnosis, and assessment of the therapeutic effect in retinal neuropathy that progresses via activation of calpain, for example, glaucoma (especially normotensive glaucoma), retinitis pigmentosa, age-related macular degeneration, retinal neuropathy and retinal vascular occlusive diseases associated with diabetes, and other such retinal diseases.
  • glaucoma especially normotensive glaucoma
  • retinitis pigmentosa for example, age-related macular degeneration, retinal neuropathy and retinal vascular occlusive diseases associated with diabetes, and other such retinal diseases.
  • compounds of the present invention emit a green fluorescence of basically the same wavelength as fluorescein
  • compounds of the present invention can be observed by a fluorescein fluorescence fundus angiograph, which is already widely used in the field of ophthalmology, and are immediately applicable to actual clinical practice.
  • a quantity of 6.3 mg (0.0198 mmol, 2 Eq) of leuco-HMRG was dissolved in 0.2 mL of dimethylsulfoxide (DMSO), 5 mg (0.0099 mmol, 1 Eq) of Ac-Leu-Leu-Tyr (OtBu)-OH, 5.7 mg (0.0150 mmol, 1.5 Eq) of O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), and 5 ⁇ L (0.0287 mmol, 2.9 Eq) of N,N-diisopropylethylamine (DIEA) were added, and stirred for two hours at 70° C.
  • DIEA N,N-diisopropylethylamine
  • Compound 2 (Ac-LM-HMRG) of the present invention was synthesized according to the following scheme 2.
  • a quantity of 10.6 mg (0.033 mmol, 12 Eq) of leuco-HMRG was dissolved in 0.3 mL of dimethylsulfoxide (DMSO), 5 mg (0.016 mmol, 1 Eq) of Ac-Leu-Met-OH, 9.5 mg (0.025 mmol, 1.5 Eq) of O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), and 8.6 ⁇ L (0.049 mmol, 3 Eq) of N,N-diisopropylethylamine (DIEA) were added, and stirred for 90 minutes at 70° C. in an argon atmosphere.
  • DIEA N,N-diisopropylethylamine
  • Probes (Ac-LLY-HMRG, Ac-LM-HMRG) in which an amino acid that is a substrate of calpain is connected by an amide bond to an amino group of the xanthene ring of HMRG are converted to HMRG when the amino acid is cut out by calpain.
  • Such a change from a closed-ring structure to an open-ring structure after the reaction causes a significant change from no absorption/no fluorescence to strong fluorescence (scheme 3).
  • a calpain enzyme addition assay was conducted in Tris buffer under the following conditions using a probe synthesized and designed by the above method. As a result, the absorption and fluorescence intensity of Ac-LLY-HMRG increased about two-fold due to the enzymatic reaction, and it was confirmed to function as a calpain probe. The results are shown in FIG. 1 a (using calpain 1) and FIG. 1 b (using calpain 2).
  • a quantity of 3 ⁇ L of a DMSO solution (1 mM) of the probe was dissolved in 3 mL of 50 mM Tris buffer (pH 7.4) (containing 5 ⁇ M of CaCl 2 ) for calpain 1 and 500 ⁇ M of CaCl 2 for calpain 2) (final probe concentration: 1 ⁇ M).
  • Calpain (2.4 units of calpain 1 and 3.8 units of calpain 2) was added, and an enzymatic reaction was conducted at 25° C.
  • the excitation wavelength was 495 nm, and the fluorescence wavelength was 524 nm.
  • Calpain 1 calpain-1 from human erythrocytes (Cat. No. 208713)
  • Calpain 2 calpain-2 from porcine kidney (Cat. No. 208715)
  • a quantity of 3 ⁇ L of a DMSO solution (1 mM) of the probe was dissolved in 3 mL of 50 mM Tris buffer (pH 7.4) (containing 5 ⁇ M of CaCl 2 ) for calpain 1 and 500 ⁇ M of CaCl 2 for calpain 2) (final probe concentration: 1 ⁇ M).
  • Calpain 24 units of calpain 1 and 38 units of calpain 2 was added, and an enzymatic reaction was conducted at 25° C.
  • the excitation wavelength was 495 nm, and the fluorescence wavelength was 524 nm.
  • Calpain 1 calpain-1 from human erythrocytes (Cat. No. 208713)
  • Calpain 2 calpain-2 from porcine kidney (Cat. No. 208715)
  • the calpain activity in HeLa cells was visualized by the following procedure using Ac-LLY-HMRG.
  • HeLa cells were incubated for one hour at 37° C. using FBS (BD Pharmingen stain buffer)-free DMEM (Dulbecco's modified Eagle's medium), and also incubated for 30 minutes by 10 ⁇ M of Ac-LLY-HMRG. Fluorescence images and transmission images were taken thereafter using a confocal microscope.
  • FBS BD Pharmingen stain buffer
  • DMEM Dulbecco's modified Eagle's medium
  • FIG. 3 the left side of FIG. 3 is the fluorescence image; the right side is the transmission image).
  • the scale bar in the drawing is 50 ⁇ m.
  • the calpain activity in HeLa cells was visualized by the following procedure using Ac-LM-HMRG.
  • addition of Ac-LM-HMRG made it possible to monitor the calpain activity inside HeLa cells.
  • addition of ALLN which is a calpain selective inhibitor, decreased the fluorescence intensity within the cells, and the fluorescence intensity decreased as the added concentration of ALLN increased.
  • the present invention makes it possible to provide new fluorescent probes having calpain as the target.
  • Ac-LLY-HMRG and Ac-LM-HMRG were demonstrated to increase in fluorescence intensity due to reaction with calpain.
  • Ac-LLY-HMRG and Ac-LM-HMRG both also presented an increase in fluorescence intensity when applied to cells.
  • the fact that the increase in the fluorescence of Ac-LM-HMRG decreased in the inhibitor addition study of Example 5 also showed that Ac-LM-HMRG permits the specific fluorescent detection of intracellular calpain activity.
  • NMDA N-methyl-D-aspartic acid
  • PBS PBS
  • Ac-LM-HMRG 2 mM, 2 ⁇ L
  • FIGS. 5 a- 5 d and FIGS. 6 a- 6 d The results are shown in FIGS. 5 a- 5 d and FIGS. 6 a- 6 d .
  • locations indicated by an arrow show nerve cells stained by HMRG.
  • FIG. 5 a no clear signal is found before Ac-LM-HMRG administration.
  • FIGS. 5 b- 5 d nerve cells were clearly stained 30, 60, and 90 minutes after administration of Ac-LM-HMRG in NMDA-administered rats (NMDA group).
  • PBS PBS-administered rats
  • FIG. 6 a no signal was found before Ac-LM-HMRG administration in PBS-administered rats (PBS) group ( FIG. 6 a ), and nerve cells were only very slightly stained after 30 minutes ( FIG. 6 b ), 60 minutes ( FIG. 6 c ), and 90 minutes ( FIG. 6 d ).
  • the fluorescent probe of the present invention is believed to be useful in the diagnosis of retinal diseases.
  • mice were injected with fluogold (FG), which is a retrograde fluorescent dye tracer, via the superior colliculus, and the retinal ganglion cells were labeled ( FIGS. 7 a and 8 a ).
  • FG fluogold
  • the mice were anesthetized by Nembutal, and 1 ⁇ L of 30 mM NMDA (PBS solution) or 1 ⁇ L of PBS was administered to the vitreous body in the eye.
  • PBS solution 30 mM NMDA
  • Ac-LM-HMRG 0.5 mM, 1 ⁇ L, PBS solution
  • Sytox registered trademark
  • Orange for staining cells that have undergone cell death, 25 ⁇ L, 1 ⁇ L, PBS solution
  • PFA paraformaldehyde
  • FIGS. 7 a- 7 c and FIGS. 8 a- 8 c The results are shown in FIGS. 7 a- 7 c and FIGS. 8 a- 8 c .
  • FIGS. 7 a- 7 c show photographs of flat-mounted retinas of the NMDA group.
  • FIG. 7 a shows an FG stained image of the NMDA group
  • FIG. 7 b shows an Ac-LM-HMRG stained image
  • FIG. 7 c shows a Sytox (registered trademark) Orange stained image.
  • calpain activity was detected by Ac-LM-HMRG in the NMDA group, and cell death was also detected.
  • FIGS. 8 a- 8 c show photographs of flat-mounted retinas of the PBS group.
  • FIG. 8 a shows an FG stained image of the PBS group
  • FIG. 8 b shows an Ac-LM-HMRG stained image
  • FIGS. 8 b and 8 c shows a Sytox (registered trademark) Orange stained image.
  • images stained by Ac-LM-HMRG and Sytox (registered trademark) Orange were not found since cell death did not occur in the PBS group.
  • the fluorescent probe of the present invention is believed to be useful in the diagnosis of retinal diseases.
  • the fluorescent probe of the present invention applies to patients with retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, or retinal neuropathy or retinal vascular occlusive disease associated with diabetes first of all makes it possible to know the calpain activity quickly in the fundus and retinal ganglion cells of the individual patient, which is expected to exert a significant effect in clinical diagnosis and treatment selection.
  • the fluorescent probe of the present invention has great medical and industrial value and economic effect, such as prescribing a calpain inhibitor for patients confirmed to have elevated calpain activity.

Abstract

[Problem] To provide a fluorescent probe that detects calpain activity in cells at high sensitivity.[Solution] A compound represented by the following general formula (I) or a salt thereof.

Description

TECHNICAL FIELD
The present invention relates to a green fluorescent probe capable of detecting the activity of calpains. The present invention also relates to diagnostic for retinal disease that uses the fluorescent probe.
BACKGROUND ART
Glaucoma is the number one cause of acquired blindness in adults in Japan, affecting an average of approximately 5% of those at least 40 years old. The definition of glaucoma is “a disease characterized by functional, structural abnormality of the eye having characteristic changes in the optic nerve and visual field in which optic nerve damage can usually be improved or suppressed by lowering the intraocular pressure sufficiently” (Non-patent Reference 1). Glaucoma is broadly classified as I) primary glaucoma, II) secondary glaucoma, and III) developmental glaucoma. I) primary glaucoma is also classified as 1) glaucoma primary open-angle glaucoma (broad sense) (A: primary open-angle glaucoma, B: normo-tensive glaucoma), 2) primary closed-angle glaucoma (A: primary closed-angle glaucoma, B: iris plateau glaucoma), and 3) mixed glaucoma (Non-patent Reference 1).
Elevated intraocular pressure is one finding often seen in glaucoma, but in Japan normotensive glaucoma in which the intraocular pressure remains constantly at a normal value during the course of development and progress of the glaucoma accounts for approximately 70% of all glaucoma patients. This is a trend seen conspicuously in Asia. The treatment method for glaucoma currently relied upon, however, is only lowering the intraocular pressure, and treatment methods for factors other than intraocular pressure are being sought.
Glaucoma in all its forms is characterized by the progressive disappearance of retinal ganglion cells (RGC) and corresponding visual field abnormalities. The disappearance of RGC has recently been suggested to be affected by calpain activity, and disappearance of RGC is reported to be decreased by administration of a calpain inhibitor in an animal model of normotensive glaucoma (Non-patent Reference 2).
The participation of calpains is also suggested in retinitis pigmentosa (RP), age-related macular degeneration (AMD), and retinal neuropathy associated with diabetic retinopathy (Non-patent References 3-6).
Further, it is thought that calpain activation participates in retinal vascular occlusive diseases such as retinal vein occlusion and retinal artery occlusion, which are ischemic diseases (Non-patent References 7 and 8).
Calpains are cysteine proteases that act Ca2+-dependently. They are expressed universally in the central nervous system and are related to neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Calpains are expressed by RGC and the nerve fiber layer in the retina (Non-patent References 9-11), and activation of calpains is confirmed in the GCL (ganglion cell layer) of retinal grafts after axotomy and in rat glaucoma models (Non-patent References 12 and 13). Calpains indirectly induce an apoptosis pathway, and, as a result, are related to the disappearance of RGC.
From this viewpoint, it is thought that being able to observe calpain activity in real time in animal models would make it possible to:
(1) clarify when, where, and how calpain activity participates in the pathology of retinal diseases and
(2) use the knowledge of (1) to assess the progress of retinal diseases and the timing of treatment intervention.
Calpain probes reported to date are:
(A) a protein-based probe in which a fluorescent protein domain is bonded to a peptide that serves as a substrate of calpain (Non-patent Reference 14) and
(B) a probe in which a dipeptide is bonded to coumarin (Non-patent Reference 15). However, the development of a calpain activity-detecting fluorescent probe that does not rely on gene introduction and does not use UV light for excitation light is required in imaging in live cells.
PRIOR ART REFERENCES Non-Patent References
  • Non-Patent Reference 1: Japan Glaucoma Society HP.
  • Non-Patent Reference 2: M Ryu, M. Yasuda, D. Shi, A. Y Shanab, R. Watanabe, N. Himori, K. Omodaka, Y Yokoyama, J. Takano, T. Saido, T. Nakazawa, J Neurosci Res. 2012, 90, 802-815.
  • Non-Patent Reference 3: Eye (2014) 28, 85-92.
  • Non-Patent Reference 4: Biochimica et Biophysica Acta 1822 (2012) 1783-1795.
  • Non-Patent Reference 5: PLOS ONE August 2013, Volume 8, Issue 8, e71650.
  • Non-Patent Reference 6: Neurobiology of Disease 48 (2012) 556-567.
  • Non-Patent Reference 7: Retinal ischemia: Mechanisms of damage and potential therapeutic strategies. Osborne N N, Casson R J, Wood J P, Chidlow G, Graham M, Melena J. Prog Retin Eye Res. 2004 January; 23(1): 91-147.
  • Non-Patent Reference 8: Degeneration and dysfunction of retinal neurons in acute ocular hypertensive rats: Involvement of calpains. Suzuki R, Oka T, Tamada Y, Shearer T R, Azuma M. J Ocul Pharmacol Ther. 2014 June; 30(5): 419-28.
  • Non-Patent Reference 9: K. Blomgren, J. O. Karlsson, Neurosci. Lett. 1990, 112, 179-183.
  • Non-Patent Reference 10: H. Persson, S. Kawashima, J. O. Karlsson, Brain Res. 1993, 611, 272-278.
  • Non-Patent Reference 11: M. Azuma, T. R. Shearer, Surv. Ophthalmol. 2008, 53, 150-163.
  • Non-Patent Reference 12: D. P. McKernan, M. B. Guerin, O'Brien, C. J., T. G. Cotter, Invest. Ophthalmol. Vis. Sci. 2007, 48, 5420-5430.
  • Non-Patent Reference 13: W. Huang, J. B. Fileta, I. Rawe, J. Qu, C. L. Grosskreutz, Invest. Ophthalmol. Vis. Sci. 2010, 51, 3049-3054.
  • Non-Patent Reference 14: P. W. Vanderklish, L. A. Krushel, B. H. Hoist, J. A. Gally, K. L. Crossin, G. M. Edelman, Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2253-2258.
  • Non-Patent Reference 15: M. Niapour, S. Berger, Cytometry A. 2007, 71, 475-485.
SUMMARY OF THE INVENTION Problems to be Solved by the Invention
The purpose of the present invention is to provide a fluorescent probe that detects calpain activity in cells at high sensitivity.
The purpose of the present invention is also to provide a diagnostic for retinal disease that, through the use of the fluorescent prove, permits real time monitoring of calpain activity and clarification of pathology, clinical diagnosis, and assessment of therapeutic effect in retinal neuropathy that progresses via activation of calpains in the field of ophthalmology.
Means for Solving the Problems
Upon in-depth studies, the present inventors discovered that a fluorescent probe the fluorescence of which rises during enzymatic reaction with calpains within cells can be provided by using HMRG as a basic skeleton and amide bonding a peptide chain to serve as a substrate for calpains, and completed the present invention.
Specifically, the present invention provides:
[1] A compound of the following general formula (I):
Figure USRE049518-20230502-C00002
wherein R1 is a hydrogen atom or from one to four of the same or different substituents that bond to the benzene ring;
R2, R3, R4, R5, R6, and R7 are, each independently, a hydrogen atom, hydroxyl group, alkyl group, or halogen atom;
R8 and R9 are, each independently, a hydrogen atom or alkyl group;
X is a C1-C3 alkylene group;
R10 is a monovalent substituent cleaved by contact with calpain;
or a salt thereof.
[2] The compound according to [1] wherein R10 is a monovalent substituent including an oligopeptide residue, or a salt thereof.
[3] The compound according to [2] wherein the monovalent substituent including an oligopeptide residue is represented by the following formula (1) or (2), or a salt thereof.
Figure USRE049518-20230502-C00003
[4] A compound of the following formula (3) or a salt thereof.
Figure USRE049518-20230502-C00004
[5] A compound of the following formula (4) or a salt thereof.
Figure USRE049518-20230502-C00005
[6] A fluorescent probe containing a compound according so to any of [1]-[5] or a salt thereof.
[7] A method for measuring calpain, comprising the following steps: (a) a step for bringing a compound according to any of [1]-[5] or a salt thereof and calpain into contact and (b) a step for measuring the fluorescence intensity of the compound produced in step (a) after contact with calpain.
[8] A diagnostic for retinal disease containing a compound according to any of [1]-[5] or a salt thereof.
[9] The diagnostic according to [8], wherein the retinal disease is glaucoma, retinitis pigmentosa, age-related macular degeneration, or retinal neuropathy or retinal vascular occlusive disease associated with diabetes.
[10] The diagnostic according to [9] wherein the glaucoma is normotensive glaucoma.
Advantages of the Invention
The use of the compound of the present invention makes it possible to provide a bright flourescent probe that can detect calpain activity in the green wavelength region, has excellent photostability, and a high quantum yield of the fluorescent substance generated by reaction with calpain.
The use of the compound of the present invention also makes it possible to provide a diagnostic of retinal diseases that permits real time monitoring of calpain activity in live cells, clarification of pathology, clinical diagnosis, and assessment of therapeutic effect in retinal diseases that progress via activation of calpain in the field of ophthalmology (for example, glaucoma, retinitis pigmentosa, age-related macular degeneration, retinal neuropathy or retinal vascular occlusive disease associated with diabetes, and other such retinal diseases). In particular, because it emits green fluorescence of basically the same wavelength as fluorescein, the compound of the present invention can be observed by a fluorescein fluorescence fundus angiograph, which is already widely used in the field of ophthalmology, and is immediately applicable to actual clinical practice.
Therefore, the present invention contributes to clarifying the pathology of retinal neuropathy that progresses via activation of calpain in the field of ophthalmology as a tool for monitoring calpain activity in live cells.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1a shows the changes in the absorption and fluorescence spectra of Ac-LLY-HMRG due to calpain addition (using calpain 1)
FIG. 1b shows the changes in the absorption and fluorescence spectra of Ac-LLY-HMRG due to calpain addition (using calpain 2)
FIG. 2a shows the changes in the absorption and fluorescence spectra of Ac-LM-HMRG due to calpain addition (using calpain 1)
FIG. 2b shows the changes in the absorption and fluorescence spectra of Ac-LM-HMRG due to calpain addition (using calpain 2)
FIG. 3 shows live cell imaging using Ac-LLY-HMRG
FIG. 4a shows live cell imaging using Ac-LM-HMRG (no ALLN added)
FIG. 4b shows live cell imaging using Ac-LM-HMRG (1 μM of ALLN added)
FIG. 4c shows live cell imaging using Ac-LM-HMRG (2 μM of ALLN added)
FIG. 4d shows live cell imaging using Ac-LM-HMRG (5 μM of ALLN added)
FIG. 5a is a fundus photograph of before Ac-LM-HMRG administration in the NMDA group
FIG. 5b is a fundus photograph of 30 minutes after Ac-LM-HMRG administration in the NMDA group
FIG. 5c is a fundus photograph of 60 minutes after Ac-LM-HMRG administration in the NMDA group
FIG. 5d is a fundus photograph of 90 minutes after Ac-LM-HMRG administration in the NMDA group
FIG. 6a is a fundus photograph of before Ac-LM-HMRG administration in the PBS group
FIG. 6b is a fundus photograph of 30 minutes after Ac-LM-HMRG administration in the PBS group
FIG. 6c is a fundus photograph of 60 minutes after Ac-LM-HMRG administration in the PBS group
FIG. 6d is a fundus photograph of 90 minutes after Ac-LM-HMRG administration in the PBS group
FIG. 7a is an FG stained image of a flat-mounted retina in the NMDA group
FIG. 7b is an HMRG stained image of a flat-mounted retina in the NMDA group
FIG. 7c is a Sytox (registered trademark) Orange stained image of a flat-mounted retina in the NMDA group
FIG. 8a is an FG stained image of a flat-mounted retina in the PBS group
FIG. 8b is an HMRG stained image of a flat-mounted retina in the PBS group
FIG. 8c is a Sytox (registered trademark) Orange stained image of a flat-mounted retina in the PBS group
 BEST MODE FOR CARRYING OUT THE INVENTION
In the present specification, an alkyl group may be any alkyl group comprising linear, branched, cyclic, or a combination thereof. The number of carbon atoms in the alkyl group is not particularly restricted; for example, about 1-6 carbon atoms or about 1-4 carbon atoms. In this specification, alkyl groups may have one or more optional substituents. Examples of substituents include, but are not limited to, an alkoxy group, halogen atom (may be any of a fluorine atom, chlorine atom, bromine atom, or iodine atom), amino group, mono- or di-substituted amino group, substituted silyl group, acyl group, or the like. When an alkyl group has two or more substituents, they may be the same or different. The same is also true for alkyl moieties of other substituents that include an alkyl moiety (for example, an alkyloxy group, aralkyl group, or the like).
In addition, in the present specification, an aryl group may be either a monocyclic aryl group or a fused polycyclic aryl group, and may include one or more heteroatoms (for example, an oxygen atom, nitrogen atom, sulfur atom, or the like) as ring members. In the present specification, an aryl group may have one or more optional substituents on its ring. Examples of substituents include, but are not limited to, an alkoxy group, halogen atom, amino group, mono- or di-substituted amino group, substituted silyl group, acyl group, or the like. When an aryl group has two or more substituents, they may be the same or different. The same is also true for aryl moieties of other substituents that include an aryl moiety (for example, an aryloxy group, aralkyl group, or the like).
One embodiment of the present invention is a compound of the following general formula (I):
Figure USRE049518-20230502-C00006
wherein, R1 is a hydrogen atom or from one to four of the same or different substituents that bond to the benzene ring;
R2, R3, R4, R5, R6, and R7 are, each independently, a hydrogen atom, hydroxyl group, alkyl group, or halogen atom;
R8 and R9 are, each independently, a hydrogen atom or alkyl group;
X is a C1-C3 alkylene group;
R10 represents a monovalent substituent cleaved by contact with calpain;
or a salt thereof.
R1 represents a hydrogen atom or from one to four substituents that bond to the benzene ring. Examples of substituents include, but are not limited to, an alkyl group, alkoxy group, halogen atom, amino group, mono- or disubstituted amino group, substituted silyl group, acyl group, or the like. When there are two or more substituents on the benzene ring, they may be the same or different. A hydrogen atom is preferred as R1.
R2, R3, R4, R5, R6, and R7 each independently represent a hydrogen atom, hydroxyl group, alkyl group, or halogen atom. R2 and R7 are preferably hydrogen atoms. R3, R4, R5, and R6 are also preferably hydrogen atoms. It is more preferred that R2, R3, R4, R5, R6, and R7 are all hydrogen atoms.
R8 and R9 each independently represent a hydrogen atom or alkyl group. When R8 and R9 both represent alkyl groups, they may be the same or different. For example, it is preferred when R8 and R9 are both hydrogen atoms or when R8 is an alkyl group and R9 is a hydrogen atom. It is more preferred that R8 and R9 are both hydrogen atoms.
X represents a C1-C3 alkylene group. An alkylene group may be a linear alkylene group or a branched alkylene group. For example, in addition to a methylene group (—CH2—), ethylene group (—CH2—CH2—), propylene group (—CH2—CH2—CH2—), —CH(CH3)—, —CH2—CH(CH3)—, —CH(CH2CH3)—, and the like can also be used as branched alkylene groups. Among these, a methylene group or ethylene group is preferred, and a methylene group is more preferred.
In general formula (I), R10 represents a monovalent substituent that is cleaved by contact with calpain. A monovalent substituent including an oligopeptide residue is preferred as the monovalent substituent that is cleaved by contact with calpain.
Monovalent substituents including an oligopeptide residue having a sequence of Leu-Leu-Tyr, Leu-Met, Leu-Leu-Val-Tyr, Thr-Pro-Leu-Leu, Thr-Pro-Leu-Lys, Thr-Pro-Leu-Phe, and Leu-Try (the amino acid at the right end of the sequence bonds directly to the NH group bonded to the xanthene skeleton) are preferred as monovalent substituents including an oligopeptide residue.
The N end of the monovalent substituent including an oligopeptide residue may be protected. Examples of protecting groups include an acetyl group, glutaryl group, succinyl group, tert-butoxycarbonyl group, benzyloxycarbonyl group, and the like, but substituents other than these may be used.
In one embodiment of the present invention, the monovalent substituent including an oligopeptide residue is represented by the following formula (1) or (2).
Figure USRE049518-20230502-C00007
One preferred embodiment of the present invention is a compound represented by the following formula (3) or (4), or a salt thereof.
Figure USRE049518-20230502-C00008
Examples of salts of compounds represented by general formula (I) and formulas (3) and (4) in the present invention include base addition salts, acid addition salts, amino acid salts, and the like. Examples of base addition salts include metal salts such as a sodium salt, potassium salt, calcium salt, magnesium salt, or the like, an ammonium salt, or an organic amine salt such as a triethylamine salt, piperidine salt, morpholine salt, or the like. Examples of acid addition salts include mineral acid salts such as a hydrochloride, sulfate, nitrate, and the like, and organic acid salts such as a methanesulfonate, p-toluenesulfonate, citrate, oxalate, and the like. Examples of amino acid salts include a glycine salt and the like. However, salts of compounds of the present invention are not limited to these.
Compounds represented by general formula (I) sometimes have one or more asymmetrical carbons in accordance with the types of substituents and can exist as stereoisomers such as optical isomers and diastereomers. Stereoisomers of a pure form, any mixtures of stereoisomers, racemic mixtures, and the like are all encompassed within the scope of the present invention. In addition, compounds represented by general formula (I) or salts thereof can also exist as hydrates or solvates. All of these are encompassed within the scope of the present invention. The type of solvent that forms a solvate is not particularly restricted; examples include ethanol, acetone, isopropanol, and other such solvents.
A fluorescent probe including a compound represented by general formula (I), formula (3), or formula (4) or a salt thereof provided by the present invention can generate a compound in which the absorption wavelength is shifted to a longer wavelength (corresponding to a compound in which R10 in the above general formula (I) is a hydrogen atom) by cleaving the R10 substituent or the monovalent substituent including an oligopeptide residue by contact with calpain, and can be used suitably as a fluorescent probe for measuring calpain.
Calpain can be measured using the above fluorescent probe in accordance with methods known to those skilled in the art. The fluorescent probe can therefore also be used as a reagent for research and also as a reagent for diagnosis of humans and animals. For example, using the above fluorescent probe makes it possible to measure the concentration and amount of a substance to be measured in a test tube. Alternatively, measurement is possible by causing the fluorescent probe to be taken up within living cells or a living body and imaging by a bioimaging technique. A typical example is a method that includes the following steps: (a) a step for bringing a compound represented by general formula (I) having a monovalent substituent that is cleaved by contact with calpain or a salt thereof and calpain into contact and (b) a step for measuring the fluorescence intensity of the compound produced in step (a) after contact with calpain.
The method for using the fluorescent probe of the present invention is not particularly restricted. Examples include measurement of the activity of isolated, purified enzymes and calpain included in cell lysate, measurement of calpain activity in living cells, measurement of the activity of enzymes that serve as a cancer biomarker in living tissues making use of the long wavelength optical property, and the like.
Another embodiment of the present invention is a diagnostic for retinal diseases including a compound and salt of the present invention.
Another embodiment of the present invention is a diagnostic for retinal neuropathy that progresses via activation of calpain in the field of ophthalmology including a compound and salt of the present invention.
Yet another embodiment of the present invention is a diagnostic for glaucoma, retinitis pigmentosa, age-related macular degeneration, retinal neuropathy or retinal vascular occlusive disease associated with diabetes (retinal vein occlusion or retinal artery occlusion) including a compound and salt of the present invention.
Yet another embodiment of the present invention is a diagnostic for glaucoma including a compound and salt of the present invention.
Yet another aspect of the present invention is a diagnostic for normotensive glaucoma including a compound and salt of the present invention.
Compounds and salts of the present invention can detect calpain activity in the green wavelength region and have excellent photostability. Their use in the field of ophthalmology therefore permits clarification of the pathology, clinical diagnosis, and assessment of the therapeutic effect in retinal neuropathy that progresses via activation of calpain, for example, glaucoma (especially normotensive glaucoma), retinitis pigmentosa, age-related macular degeneration, retinal neuropathy and retinal vascular occlusive diseases associated with diabetes, and other such retinal diseases.
In addition, since compounds of the present invention emit a green fluorescence of basically the same wavelength as fluorescein, compounds of the present invention can be observed by a fluorescein fluorescence fundus angiograph, which is already widely used in the field of ophthalmology, and are immediately applicable to actual clinical practice.
EXAMPLES
The present invention is explained more concretely below through examples. The scope of the present invention, however, is not limited to the following examples.
Synthesis Example 1
Compound 1 (Ac-LLY-HMRG) of the present invention was synthesized according tyo the following scheme 1.
Figure USRE049518-20230502-C00009
(1) Synthesis of Leuco-HMRG
Three hundred sixty-two grams (0.986 mmol, 1 Eq) of Rhodamin 110 and 400 μL (7.504 mmol, 7.6 Eq) of sulfuric acid were dissolved in 40 mL of methanol and stirred overnight at 80° C. The reaction solvent was removed under reduced pressure, and the product was neutralized by sodium bicarbonate aqueous solution. The solid obtained was extracted by water and methanol. The solvent of the organic layer was removed, and a solid was obtained. The solid was then dissolved in 60 mL of THF, 247.8 mg (6.53 mmol, 6.6 Eq) of LAH was added while cooling by ice, and the solution was stirred overnight at 0° C. in an argon atmosphere. After quenching by methanol, 50 mL of dichloromethane and 100 mL of Rochelle salt aqueous solution were added and stirred overnight. Water was added to the reaction mixture, which was then extracted by dichloroethane and washed with brine. Sodium sulfate was added to the organic layer, the solvent was removed after filtration, and a solid was obtained. The solid was purified by silica gel chromatography (dichloromethane/methanol=97/3), and the target compound (64 mg, 21%) was obtained.
1H NMR (400 MHz, DMSO): δ 7.36-7.34 (m, 1H), 7.12-7.10 (m, 2H), 6.96-6.94 (m, 1H), 6.59 (d, 2H, J=8.2 Hz), 6.24 (d, 2H, J=2.2 Hz), 6.16 (dd, 2H, J=8.2 Hz, 2.2 Hz), 5.29 (s, 1H), 5.19 (t, 1H, J=4.9 Hz), 5.07 (s, 4H), 4.54 (d, 2H, J=4.9 Hz). The HRMS (ESI+) was calculated for [M+Na]+ as 341.12605; The value found was 341.12576 (−0.29 mmu).
(2) Synthesis of Ac-LLY-HMRG (Compound 1 of the Present Invention)
A quantity of 6.3 mg (0.0198 mmol, 2 Eq) of leuco-HMRG was dissolved in 0.2 mL of dimethylsulfoxide (DMSO), 5 mg (0.0099 mmol, 1 Eq) of Ac-Leu-Leu-Tyr (OtBu)-OH, 5.7 mg (0.0150 mmol, 1.5 Eq) of O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), and 5 μL (0.0287 mmol, 2.9 Eq) of N,N-diisopropylethylamine (DIEA) were added, and stirred for two hours at 70° C. in an argon atmosphere. Water was added to the reaction mixture, which was extracted by ethyl acetate and washed with brine. After drying the organic layer by sodium sulfate, the solvent was evaporated under reduced pressure. A quantity of 8.0 mg (0.0099 mmol, 1 Eq) of the residue and 6.6 mg (0.0268 mmol, 2.7 Eq) of chloranil were dissolved in dichloromethane solution and stirred for 30 minutes at room temperature. A quantity of 58 μL (0.495 mmol, 50 Eq) of thioanisole and 2 mL of trifluoroacetic acid (TFA) were then added, stirred for seven hours, and crudely purified by a short column. Next, purification was performed by HPLC (eluent A (99% H2O (0.1% TFA)/1% CH3CN) and eluent B (99% CH3CN, 1% H2O) (A/B=90/10 to 10/90, 20 min)), and the target compound (1.4 mg, 19% (in two steps)) was obtained.
The HRMS (ESI+) was calculated for [M+H]+ as 748.37048; The value found was 748.36998 (−0.5 mmu).
Synthesis Example 2
Compound 2 (Ac-LM-HMRG) of the present invention was synthesized according to the following scheme 2.
Figure USRE049518-20230502-C00010
(1) Synthesis of Ac-LM-Leuco-HMRG
A quantity of 10.6 mg (0.033 mmol, 12 Eq) of leuco-HMRG was dissolved in 0.3 mL of dimethylsulfoxide (DMSO), 5 mg (0.016 mmol, 1 Eq) of Ac-Leu-Met-OH, 9.5 mg (0.025 mmol, 1.5 Eq) of O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HATU), and 8.6 μL (0.049 mmol, 3 Eq) of N,N-diisopropylethylamine (DIEA) were added, and stirred for 90 minutes at 70° C. in an argon atmosphere. Water was added to the reaction mixture, which was extracted by ethyl acetate and washed with brine. After drying the organic layer by sodium sulfate, the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane/methanol=91/9), and the target compound (8.1 mg, 82%) was obtained.
The HRMS (ESI+) was calculated for [M+Na]+ as 627.26116; The value found was, 627.25978 (−1.4 mmu).
(2) Synthesis of Ac-LM-HMRG (Compound 2 of the Present Invention
A quantity of 8.1 mg (0.0134 mmol, 1 Eq) of Ac-LM-leuco-HMRG and 9.2 mg (0.0374 mmol, 2.8 Eq) of chloranil were dissolved in dichloromethane solution and stirred for 30 minutes at room temperature. After crude purification by a short column, purification was conducted using HPLC (eluent A (99% H2O (0.1% TFA)/1% CH3CN) and eluent B (99% CH3CN, 1% H2O) (A/B=75/25 to 25/75, 30 min)), and the target compound (1.3 mg, 13% (in two steps)) was obtained.
The HRMS (ESI+) was calculated for [M+H]+ as 603.26357 The value found was 603.26343 (−0.13 mmu).
Reaction Mechanism of Calpain Probes (Ac-LLY-HMRG, Ac-LM-HMRG)
Probes (Ac-LLY-HMRG, Ac-LM-HMRG) in which an amino acid that is a substrate of calpain is connected by an amide bond to an amino group of the xanthene ring of HMRG are converted to HMRG when the amino acid is cut out by calpain. Such a change from a closed-ring structure to an open-ring structure after the reaction causes a significant change from no absorption/no fluorescence to strong fluorescence (scheme 3).
Figure USRE049518-20230502-C00011
Example 1
Measurement of the Optical Properties of Ac-LLY-HMRG and Ac-LM-HMRG
The optochemical properties of Ac-LLY-HMRG and Ac-LM-HMRG were measured in 0.2 M sodium phosphate buffer of pH 2. Table 1 below also shows the optochemical properties of HMRG, which is the enzymatic reaction product.
TABLE 1
Absmax Emmax
[nm] [nm] Φn
Ac-LLY-HMRG 470 526 0.19
Ac-LM-HMRG 470 529 0.32
HMRG 501 524 0.81
Example 2
Evaluation of Ac-LLY-HMRG as a Fluorescent Probe (In Vitro Enzyme Assay Using Calpain)
A calpain enzyme addition assay was conducted in Tris buffer under the following conditions using a probe synthesized and designed by the above method. As a result, the absorption and fluorescence intensity of Ac-LLY-HMRG increased about two-fold due to the enzymatic reaction, and it was confirmed to function as a calpain probe. The results are shown in FIG. 1a (using calpain 1) and FIG. 1b (using calpain 2).
(Experimental Conditions)
A quantity of 3 μL of a DMSO solution (1 mM) of the probe was dissolved in 3 mL of 50 mM Tris buffer (pH 7.4) (containing 5 μM of CaCl2) for calpain 1 and 500 μM of CaCl2 for calpain 2) (final probe concentration: 1 μM). Calpain (2.4 units of calpain 1 and 3.8 units of calpain 2) was added, and an enzymatic reaction was conducted at 25° C. The excitation wavelength was 495 nm, and the fluorescence wavelength was 524 nm.
(Enzymes)
Calpain 1: calpain-1 from human erythrocytes (Cat. No. 208713)
Calpain 2: calpain-2 from porcine kidney (Cat. No. 208715)
Example 3
Evaluation of Ac-LM-HMRG as a Fluorescent Probe (In Vitro Enzyme Assay Using Calpain)
A calpain enzyme addition assay was conducted in Tris buffer using a probe synthesized and designed by the above method. As a result, the absorption and fluorescence intensity of Ac-LM-HMRG increased about four-fold due to the enzymatic reaction with calpain 2, and it was confirmed to function as a calpain probe. The results are shown in FIG. 2a (using calpain 1) and FIG. 2b (using calpain 2).
(Experimental Conditions)
A quantity of 3 μL of a DMSO solution (1 mM) of the probe was dissolved in 3 mL of 50 mM Tris buffer (pH 7.4) (containing 5 μM of CaCl2) for calpain 1 and 500 μM of CaCl2 for calpain 2) (final probe concentration: 1 μM). Calpain (24 units of calpain 1 and 38 units of calpain 2) was added, and an enzymatic reaction was conducted at 25° C. The excitation wavelength was 495 nm, and the fluorescence wavelength was 524 nm.
(Enzymes)
Calpain 1: calpain-1 from human erythrocytes (Cat. No. 208713)
Calpain 2: calpain-2 from porcine kidney (Cat. No. 208715)
Example 4
Live Cell Imaging Using Ac-LLY-HMRG
The calpain activity in HeLa cells was visualized by the following procedure using Ac-LLY-HMRG.
(Experimental Procedure)
(a) HeLa cells were incubated for one hour at 37° C. using FBS (BD Pharmingen stain buffer)-free DMEM (Dulbecco's modified Eagle's medium), and also incubated for 30 minutes by 10 μM of Ac-LLY-HMRG. Fluorescence images and transmission images were taken thereafter using a confocal microscope.
The results are shown in FIG. 3 (the left side of FIG. 3 is the fluorescence image; the right side is the transmission image). The scale bar in the drawing is 50 μm.
As shown in FIG. 3 , addition of Ac-LLY-HMRG made it possible to monitor the calpain activity inside HeLa cells.
Example 5
Live Cell Imaging Using Ac-LM-HMRG
The calpain activity in HeLa cells was visualized by the following procedure using Ac-LM-HMRG.
(Experimental Procedure)
(a) HeLa cells were incubated for one hour at 37° C. using FBS (BD Pharmingen stain buffer)-free DMEM (Dulbecco's modified Eagle's medium), (b) 1 μM ALLN (calpain selective inhibitor)-containing DMEM (FBS (−)), (c) 2 μM ALLN-containing DMEM (FBS (−)), and (d) 5 μM ALLN-containing DMEM (FBS (−)), and also incubated for 30 minutes by 10 μM of Ac-LM-HMRG. Fluorescence images and transmission images were taken thereafter using a confocal microscope. The results are shown in FIGS. 4a-4d (the left side of each drawing is the fluorescence image; the right side is the transmission image). The scale bar in the drawing is 50 μm.
As shown in FIG. 4a, addition of Ac-LM-HMRG made it possible to monitor the calpain activity inside HeLa cells. Also, as shown in FIGS. 4b-4d, addition of ALLN, which is a calpain selective inhibitor, decreased the fluorescence intensity within the cells, and the fluorescence intensity decreased as the added concentration of ALLN increased.
As illustrated in the above examples, the present invention makes it possible to provide new fluorescent probes having calpain as the target. Specifically, as shown in Examples 2 and 3, Ac-LLY-HMRG and Ac-LM-HMRG were demonstrated to increase in fluorescence intensity due to reaction with calpain. Ac-LLY-HMRG and Ac-LM-HMRG both also presented an increase in fluorescence intensity when applied to cells. The fact that the increase in the fluorescence of Ac-LM-HMRG decreased in the inhibitor addition study of Example 5 also showed that Ac-LM-HMRG permits the specific fluorescent detection of intracellular calpain activity.
Example 6
Evaluation of Ac-LM-HMRG Using a Rat NMDA Injury Model
(Experimental Procedure)
SD rats were placed under general anesthesia using Nembutal. N-methyl-D-aspartic acid (NMDA) (10 mM, 2 μL) or PBS was administered to the eye. The animals were again placed under anesthesia by ketamine-xylazine mixture four hours later, and Ac-LM-HMRG (2 mM, 2 μL) was administered to the eye. The fundus was photographed by an F10 (Nidec confocal biomicroscope).
The results are shown in FIGS. 5a-5d and FIGS. 6a-6d. In FIGS. 5 and 6 , locations indicated by an arrow show nerve cells stained by HMRG.
As shown in FIG. 5a, no clear signal is found before Ac-LM-HMRG administration. However, as shown in FIGS. 5b-5d, nerve cells were clearly stained 30, 60, and 90 minutes after administration of Ac-LM-HMRG in NMDA-administered rats (NMDA group). On the other hand, no signal was found before Ac-LM-HMRG administration in PBS-administered rats (PBS) group (FIG. 6a), and nerve cells were only very slightly stained after 30 minutes (FIG. 6b), 60 minutes (FIG. 6c), and 90 minutes (FIG. 6d).
Given that the rat NMDA injury model is believed to be a retinal disease model, the fluorescent probe of the present invention is believed to be useful in the diagnosis of retinal diseases.
Example 7
Evaluation of Ac-LM-HMRG Using Flat-Mounted Retinas with Mouse NMDA Injury Model
(Experimental Procedure)
A study by mouse NMDA injury model was conducted with flat-mounted retinas. First, male BL6/J mice were injected with fluogold (FG), which is a retrograde fluorescent dye tracer, via the superior colliculus, and the retinal ganglion cells were labeled (FIGS. 7a and 8a). After one week, the mice were anesthetized by Nembutal, and 1 μL of 30 mM NMDA (PBS solution) or 1 μL of PBS was administered to the vitreous body in the eye. Two weeks later, the mice were again anesthetized by ketamine-xylazine, and Ac-LM-HMRG (0.5 mM, 1 μL, PBS solution) was administered to the eye. One hour after Ac-LM-HMRG administration, Sytox (registered trademark) Orange (for staining cells that have undergone cell death, 25 μL, 1 μL, PBS solution) (manufactured by Invitrogen) was administered to the vitreous body. Ten minutes later, the eyeball was removed, fixed for two hours by 4% paraformaldehyde (PFA), and flat-mounted retinas were prepared.
The results are shown in FIGS. 7a-7c and FIGS. 8a-8c.
FIGS. 7a-7c show photographs of flat-mounted retinas of the NMDA group. FIG. 7a shows an FG stained image of the NMDA group, FIG. 7b shows an Ac-LM-HMRG stained image, and FIG. 7c shows a Sytox (registered trademark) Orange stained image. As shown in FIGS. 7b and 7c, calpain activity was detected by Ac-LM-HMRG in the NMDA group, and cell death was also detected. FIGS. 8a-8c show photographs of flat-mounted retinas of the PBS group. FIG. 8a shows an FG stained image of the PBS group, FIG. 8b shows an Ac-LM-HMRG stained image, and FIG. 8c shows a Sytox (registered trademark) Orange stained image. As shown in FIGS. 8b and 8c, images stained by Ac-LM-HMRG and Sytox (registered trademark) Orange were not found since cell death did not occur in the PBS group.
Given that the mouse NMDA injury model is believed to be a retinal disease model, the fluorescent probe of the present invention is believed to be useful in the diagnosis of retinal diseases.
Applying the fluorescent probe of the present invention to patients with retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, or retinal neuropathy or retinal vascular occlusive disease associated with diabetes first of all makes it possible to know the calpain activity quickly in the fundus and retinal ganglion cells of the individual patient, which is expected to exert a significant effect in clinical diagnosis and treatment selection. Specifically, the fluorescent probe of the present invention has great medical and industrial value and economic effect, such as prescribing a calpain inhibitor for patients confirmed to have elevated calpain activity.

Claims (9)

The invention claimed is:
1. A compound of the following general formula (I):
Figure USRE049518-20230502-C00012
wherein R1 is a hydrogen atom or from one to four of the same or different substituents that bond to the benzene ring;
R2, R3, R4, R5, R6, and R7 are, each independently, a hydrogen atom, hydroxyl group, alkyl group, or halogen atom;
R8 and R9 are, each independently, a hydrogen atom or alkyl group;
X is a C1-C3 alkylene group;
R10 is selected from the following formula (1) or (2);
Figure USRE049518-20230502-C00013
a monovalent substituent cleaved by contact with calpain, and said monovalent substituent consists of an oligopeptide residue having a sequence of Leu-Leu-Tyr or Leu-Met (the amino acid at the right end of the sequence bonds directly to the NH group bonded to the xanthene skeleton), the N end of said oligopeptide residue may be protected;
or a salt thereof.
2. A compound of the following formula (3) or a salt thereof
Figure USRE049518-20230502-C00014
3. A compound of the following formula (4) or a salt thereof
Figure USRE049518-20230502-C00015
4. A fluorescent probe containing a compound according to claim 1 or a salt thereof.
5. A method for measuring calpain, comprising the following steps: (a) a step for bringing a compound according to claim 1 or a salt thereof and calpain into contact and (b) a step for measuring the fluorescence intensity of the compound produced in step (a) after contact with calpain.
6. A diagnostic for retinal disease containing a compound according to claim 1 or a salt thereof.
7. The diagnostic according to claim 6 wherein the retinal disease is glaucoma, retinitis pigmentosa, age-related macular degeneration, retinal neuropathy or retinal vascular occlusive disease associated with diabetes.
8. The diagnostic according to claim 7 wherein the glaucoma is normotensive glaucoma.
9. The compound of claim 1, wherein R10 is selected from the following formula (1) or (2);
Figure USRE049518-20230502-C00016
US17/327,001 2015-02-27 2016-02-29 Fluorescent probe for detecting calpain activity Active USRE49518E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/327,001 USRE49518E1 (en) 2015-02-27 2016-02-29 Fluorescent probe for detecting calpain activity

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2015-039502 2015-02-27
JP2015039502 2015-02-27
US15/553,970 US10294240B2 (en) 2015-02-27 2016-02-29 Fluorescent probe for detecting calpain activity
US17/327,001 USRE49518E1 (en) 2015-02-27 2016-02-29 Fluorescent probe for detecting calpain activity
PCT/JP2016/056030 WO2016137004A1 (en) 2015-02-27 2016-02-29 Fluorescent probe for detecting calpain activity

Publications (1)

Publication Number Publication Date
USRE49518E1 true USRE49518E1 (en) 2023-05-02

Family

ID=56788587

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/327,001 Active USRE49518E1 (en) 2015-02-27 2016-02-29 Fluorescent probe for detecting calpain activity
US15/553,970 Ceased US10294240B2 (en) 2015-02-27 2016-02-29 Fluorescent probe for detecting calpain activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/553,970 Ceased US10294240B2 (en) 2015-02-27 2016-02-29 Fluorescent probe for detecting calpain activity

Country Status (4)

Country Link
US (2) USRE49518E1 (en)
EP (2) EP3954697B1 (en)
JP (1) JP6881294B2 (en)
WO (1) WO2016137004A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10383956B2 (en) 2014-07-11 2019-08-20 The University Of Tokyo Fluorescent probe for detecting dipeptidyl peptidase IV
KR102186097B1 (en) * 2017-12-26 2020-12-03 주식회사 엘지화학 Xanthene-based compound and photosensitive resin composition comprising the same
JPWO2021070906A1 (en) * 2019-10-09 2021-04-15
WO2022270607A1 (en) * 2021-06-24 2022-12-29 株式会社 東北テクノアーチ Fluorescent probes

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072807A1 (en) * 1999-10-22 2007-03-29 Smithkline Beecham Corporation & Smithkline Beecham P.L.C. Method of screening compounds
WO2010095450A1 (en) 2009-02-20 2010-08-26 国立大学法人 東京大学 Fluorescent probe for use in measurement of protease
US20130023675A1 (en) * 2010-01-13 2013-01-24 The University Of Tokyo Diagnostic for cancer
WO2013180181A1 (en) 2012-05-30 2013-12-05 国立大学法人 東京大学 Fluorescent probe for high-sensitivity pancreatic fluid detection, and method for detecting pancreatic fluid
WO2014136780A1 (en) 2013-03-04 2014-09-12 国立大学法人 東京大学 Fluorescent probe for detecting activity of calpain
WO2016006678A1 (en) 2014-07-11 2016-01-14 国立大学法人 東京大学 Fluorescent probe for detecting dipeptidyl peptidase iv
US20170073321A1 (en) * 2014-05-14 2017-03-16 The University Of Tokyo Enzyme-specific fluorescent compound capable of being retained in cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1517997A4 (en) * 2002-05-24 2006-11-15 Molecular Devices Corp Luminogenic protease substrates

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072807A1 (en) * 1999-10-22 2007-03-29 Smithkline Beecham Corporation & Smithkline Beecham P.L.C. Method of screening compounds
US8461358B2 (en) * 2009-02-20 2013-06-11 The University Of Tokyo Fluorescent probe for measuring protease
WO2010095450A1 (en) 2009-02-20 2010-08-26 国立大学法人 東京大学 Fluorescent probe for use in measurement of protease
US20120052518A1 (en) 2009-02-20 2012-03-01 The University Of Tokyo Fluorescent probe for measuring protease
US20140206992A1 (en) * 2010-01-13 2014-07-24 The University Of Tokyo Method for diagnosing cancer
US20130023675A1 (en) * 2010-01-13 2013-01-24 The University Of Tokyo Diagnostic for cancer
US9610366B2 (en) * 2010-01-13 2017-04-04 The University Of Tokyo Method for diagnosing cancer
WO2013180181A1 (en) 2012-05-30 2013-12-05 国立大学法人 東京大学 Fluorescent probe for high-sensitivity pancreatic fluid detection, and method for detecting pancreatic fluid
US20150152469A1 (en) 2012-05-30 2015-06-04 The University Of Tokyo Fluorescent probe for high-sensitivity pancreatic fluid detection, and method for detecting pancreatic fluid
US9506102B2 (en) * 2012-05-30 2016-11-29 The University Of Tokyo Fluorescent probe for high-sensitivity pancreatic fluid detection, and method for detecting pancreatic fluid
WO2014136780A1 (en) 2013-03-04 2014-09-12 国立大学法人 東京大学 Fluorescent probe for detecting activity of calpain
US20160102336A1 (en) 2013-03-04 2016-04-14 The University Of Tokyo Fluorescent probe for detecting activity of calpain
US20170073321A1 (en) * 2014-05-14 2017-03-16 The University Of Tokyo Enzyme-specific fluorescent compound capable of being retained in cells
WO2016006678A1 (en) 2014-07-11 2016-01-14 国立大学法人 東京大学 Fluorescent probe for detecting dipeptidyl peptidase iv
US20170157272A1 (en) * 2014-07-11 2017-06-08 The University Of Tokyo Fluorescent probe for detecting dipeptidyl peptidase iv

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
Azuma, M., et al., Errata, Survey of Ophthalmology 53(3):308-310, 2008.
Barnett, E.M., et al., Single-Cell Imaging of Retinal Ganglion Cell Apoptosis With a Cell-Penetrating, Activatable Peptide Probe in an in Vivo Glaucoma Model, PNAS 106(23):9391-9396, Jun. 9, 2009.
Blomgren, K., and J.-O. Karlsson, Calpain and Calpastatin Activity in the Optic Pathway, Neuroscience Letters 112:179-183, 1990.
Extended European Search Report received in connection with European Patent Application No. 16755748.7 dated Oct. 24, 2018.
Fujii, T., et al., In vivo Imaging of Intraperitoneally Disseminated Tumors in Model Mice by Using Activatable Fluorescent Small-Molecular Probes for Activity of Cathepsins, Bioconjugate Chemistry 25(10):1838-1846, Published Sep. 5, 2014.
Fujii, T., et al., In vivo Imaging of Intraperitoneally Disseminated Tumors in Model Mice by Using Activatable Fluorescent Small—Molecular Probes for Activity of Cathepsins, Bioconjugate Chemistry 25(10):1838-1846.
Glaucoma Clinical Practice Guidelines, 3rd Edition, copyright 2012, Japan Glaucoma Society, Chika Prefecture Matsudo-shi, Gokanishi, X-Abs.
Glaucoma Clinical Practice Guidelines, 3rd Edition, copyright 2012, Japan Glaucoma Society, Chika Prefecture Matsudo-shi, Gokanishi.
Hinman, J.D., et al., Activation of Calpain-1 in Myelin and Microglia in the White Matter of the Aged Rhesus Monkey, Journal of Neurochemistry 89(2):430-441, 2004.
Huang, W., et al., Calpain Activation in Experimental Glaucoma, Investigative Ophthalmology & Visual Science 51(6):3049-3054, 2010.
International Search Report and Written Opinion issued in Application No. PCT/JP2016/056030 dated May 24, 2016.
Leytus, S.P., Rhodamine-based compounds as fluorogenic substrates for serine proteinases, Biochem. J. 209:299-307, 1983.
Leytus; Biochem. J. (1983) 209, 299-307. (Year: 1983). *
Liu, L., et al., μ-Calpain Regulates Caspase-Dependent and Apoptosis Inducing Factor-Mediated Caspase-Independent Apoptotic Pathways in Cisplatin-Induced Apoptosis, International Journal of Cancer 125(12):2757-2766, 2009.
McKernan, D.P., et al., A Key Role for Calpains in Retinal Ganglion Cell Death, Investigative Ophthalmology & Visual Science 48(12):5420-5430, 2007.
Mitto, S., et al., Synthesis and Evaluation of Fluorescent Probes for the Detection of Calpain Activity, Analytical Biochemistry 319:234-238, Aug. 15, 2003.
Mittoo, S., et al., Synthesis and Evaluation of Fluorescent Probes for the Detection of Calpain Activity, Analytical Biochemistry 319:234-238, Aug. 15, 2003.
Mittoo; Analytical Biochemistry 319 (2003) 234-238. (Year: 2003). *
Nakajima, E., et al., Activation of the Mitochondrial Caspase Pathway and Subsequent Calpain Activation in Monkey RPE Cells Cultured Under Zinc Depletion, Eye 28:85-92, 2014.
Niapour, M., and S. Berger, Flow Cytometric Measurement of Calpain Activity in Living Cells, International Society for Analytical Cytology, Cytometry Part A 71A:475-485, 2007.
O'Brien, M., et al., Light Up your Calpain Activity Calpain no Kassei Seibutsu Hakko Assay, Prometech Journal, No. 18, pp. 3-6, 2005, X-Abs.
O'Brien, M., et al., Light Up your Calpain Activity Calpain no Kassei Seibutsu Hakko Assay, Prometech Journal, No. 18, pp. 3-6, 2005.
Osborne, N.N., et al., Retinal Ischemia: Mechanisms of Damage and Potential Therapeutic Strategies, Progress in Retinal and Eye Research 23:91-147, 2004.
Ozaki, T., et al., Inhibitory Peptide of Mitochondrial u-Calpain Protects Against Photoreceptor Degeneration in Rhodopsin Transgenic S334ter and P23H Rats, Plos One 8(8):1-10, 2013, www.plosone.org.
Ozaki, T., et al., Intravitreal Injection or Topical Eye-Drop Application of a μ-calpain C2L Domain Peptide Protects Against Photoreceptor Cell Death in Royal College of Surgeons' Rats, A Model of Retinitis Pigmentosa, Biochimica et Biophysica Acta 1822:1783-1795, 2012.
Persson, H., et al., Immunohistochemical Localization of Calpains and Calpastatin in the Rabbit Eye, Brain Research 611:272-278, 1993.
Rosser, B.G. et al., Calpain Activity Increases in Hepatocytes Followiing Addition of ATP. Demonstration by a Novel fluorescent Approach, Journal of Biological Chemistry 268(31):23593-23600, 1993.
Rosser, B.G., et al., Calpain Activity Increases in Hepatocytes Following Addition of ATP. Demonstration by a Novel fluorescent Approach, Journal of Biological Chemistry 268(31):23593-23600, 1993.
Rosser, B.G., et al., Cellular In Vivo Assay of Calpain Activity Using a Fluorescent Substrate, Methods in Molecular Biology, 144:245-259, 2000.
Rosser; Methods in Molecular Biology 2000, 144, 245-259. (Year: 2000). *
Ryu, M., et al. Critical role of Calpain in Axonal Damage-Induced Retinal Ganglion Cell Death, Journal of Neuroscience Research 90:802-815, 2012.
Sakabe, M., et al., Rational Design of Highly Sensitive Fluorescence Probes for Protease and Glycosidase Based on Precisely Controlled Spirocyclization, Journal of the American Chemical Society 135(1):409-414, 2013.
Sakabe; J. Am. Chem. Soc. 2013, 135, 409-414. (Year: 2013). *
Shanab, A.Y., et al., Metabolic Stress Response Implicated in Diabetic Retinopathy: The Role of Calpain, and the Therapeutic Impact of Calpain Inhibitor, Neurobiology of Disease 48:556-567, 2012.
Shinkai-Ouchi, F., et al., Predictions of Cleavability of Calpain Proteolysis by Quantitative Structure-Activity Relationship Analysis Using Newly Determined Cleavage Sites and Catalytic Efficiencies of an Oligopeptide Array, Mol. Cell. Proteomics, 15:1262-1280, 2016.
Shinkai-Ouchi; Mol Cell Proteomics 2016, 15, 1262-1280. (Year: 2016). *
Suzuki, R., et al., Degeneration and Dysfunction of Retinal Neurons in Acute Ocular Hypertensive Rats: Involvement of Calpains, Journal of Ocular Pharmacology and Therapeutics 30(5):419-428, 2014.
Vanderklish, P.W., et al., Marking Synaptic Activity in Dendritic Spines With a Calpain Substrate Exhibiting Fluorescence Resonance Energy Transfer, PNAS 97(5):2253-2258, 2000.
Vanderklish, P.W., et al., Marking Synaptic Activity in Dendritic Spines With a Calpain Substrate Exhibiting Fluorescense Resonance Energy Transfer, PNAS 97(5):2253-2258, 2000.

Also Published As

Publication number Publication date
EP3275889A1 (en) 2018-01-31
EP3954697B1 (en) 2024-01-03
WO2016137004A1 (en) 2016-09-01
US20180162871A1 (en) 2018-06-14
EP3954697A1 (en) 2022-02-16
EP3275889A4 (en) 2018-11-21
JP6881294B2 (en) 2021-06-02
US10294240B2 (en) 2019-05-21
JPWO2016137004A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
USRE49518E1 (en) Fluorescent probe for detecting calpain activity
US9329184B2 (en) Fluorescent probe
US11160880B2 (en) Compositions and methods for assessing eye vasculature
US20120042398A1 (en) Compositions for labeling and identifying autophagosomes and methods for making and using them
US20160102336A1 (en) Fluorescent probe for detecting activity of calpain
JP5887011B2 (en) Fluorescent probe
FR2894963A1 (en) NEW COMPOUNDS INTERACTING WITH PEA-15
JP7140398B2 (en) Nitrobenzene derivative or salt thereof and uses thereof
WO2016090169A1 (en) Intracellular caspase probes for detection of apoptosis and inflammation and kits containing such probes
JP2018145126A (en) Fluorescent probe for detection of carboxypeptidase activity
US9255933B2 (en) Imaging beta-amyloid peptides and inhibition of beta-amyloid peptide aggregation
WO2019117812A1 (en) Near infra-red molecular probes for use in diagnosis of fibrotic conditions and screening of anti-fibrotic drugs
US8632749B2 (en) Two photon tracer, method for the preparation thereof and the use thereof in screening anticancer agents
WO2018105667A1 (en) Fluorescent probe for aldh3a1 detection
US20220341922A1 (en) Fluorescent probe for use in detection of brain tumor
JP7100363B2 (en) Deep red fluorescent probe
US20220017940A1 (en) Fluorescent probe for detecting carboxypeptidase activity
US9403794B2 (en) Imaging beta-amyloid peptides and inhibition of beta-amyloid peptide aggregation
WO2014063033A2 (en) Novel probes and targeting comounds for mitochondria

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY